πŸ‡ΊπŸ‡Έ FDA
Patent

US 8592442

Nilotinib HCl crystalline forms

granted A61PA61P35/00A61P35/02

Quick answer

US patent 8592442 (Nilotinib HCl crystalline forms) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Nov 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00